A rapid CRISPR competitive assay for in vitro and in vivo discovery of potential drug targets affecting the hematopoietic system
CRISPR/Cas9 can be used as an experimental tool to inactivate genes in cells. However, a CRISPR-targeted cell population will not show a uniform genotype of the targeted gene. Instead, a mix of genotypes is generated - from wild type to different forms of insertions and deletions. Such mixed genotyp...
Main Authors: | Yunbing Shen, Long Jiang, Vaishnavi Srinivasan Iyer, Bruno Raposo, Anatoly Dubnovitsky, Sanjaykumar V. Boddul, Zsolt Kasza, Fredrik Wermeling |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Computational and Structural Biotechnology Journal |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2001037021004050 |
Similar Items
-
Designing custom CRISPR libraries for hypothesis-driven drug target discovery
by: Vaishnavi Srinivasan Iyer, et al.
Published: (2020-01-01) -
In vitro and ex vitro functional characterization of human HLA-DRB1∗04 restricted T cell receptors
by: Sanjaykumar V. Boddul, et al.
Published: (2021-01-01) -
The hematopoietic stroma
by: N.B. Nardi, et al.
Published: (1999-05-01) -
Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline
by: Carles Cornet, et al.
Published: (2018-07-01) -
Comprehensive Proteomic Characterization of Ontogenic Changes in Hematopoietic Stem and Progenitor Cells
by: Maria Jassinskaja, et al.
Published: (2017-12-01)